Annals of Indian Academy of Neurology
ORIGINAL ARTICLE
Year
: 2022  |  Volume : 25  |  Issue : 3  |  Page : 433--440

Efficacy and tolerability of erenumab for prevention of episodic migraine in India


Debashish Chowdhury1, Jaydip R Chaudhuri2, Pahari Ghosh3, Rahul Kulkarni4, Sumit Singh5, Sneha Thakur6, Anup V Thorat6 
1 Department of Neurology, Govind Ballabh Pant Hospital, New Delhi, India
2 Department of Neurology, Yashoda Hospital, Hyderabad, Telangana, India
3 Department of Neurology, Calcutta Medical Research Centre, Kolkata, West Bengal, India
4 Department of Neurology, Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India
5 Department of Neurology, Agrim Institute of Neurosciences, Artemis Hospitals, Gurgaon, Haryana, India
6 Medical Affairs, Novartis India Limited, Mumbai, Maharashtra, India

Correspondence Address:
Debashish Chowdhury
Director, Professor and Head, Department of Neurology, Govind Ballabh Pant Hospital, New Delhi
India

Background: EMPOwER, a 12-week, double-blind (DB), randomized, placebo-controlled study evaluated the efficacy and safety of erenumab in adult patients with episodic migraine (EM) from Asia, the Middle East, and Latin America. This study analyzes the Indian experience for the use of erunumab for prevention of episodic migraine. Objective: The study aimed to evaluate the efficacy and tolerability of erenumab (70 mg and 140 mg) in EM patients from India. Methods: Randomized patients received monthly subcutaneous injections of placebo and erenumab 70 mg or 140 mg for 3 months. The primary endpoint was a change from the baseline in monthly migraine days (MMDs) at month 3. Other endpoints included achievement of ≥50%, ≥75%, and 100% reduction in MMD; a change in monthly acute migraine-specific medication treatment days; a change in patient-reported outcomes; and safety assessment. Results: Of the 539 patients screened, 351 patients were randomized (erenumab, 70 mg: n = 133 and 140 mg: n = 94; placebo: n = 124). The mean (±SD) age, disease duration, and MMD were 35.1 (±8.6) years, 6.77 (±6.01) years, and 7.82 (±2.89) days, respectively. The placebo-adjusted difference in mean MMD for erenumab 70 mg was -0.88 (95% CI, -2.16, 0.39; P = 0.174) days, and that for erenumab 140 mg was -1.01 (-2.42, 0.41; P = 0.164) days versus placebo. Secondary and exploratory endpoints demonstrated consistently better results in both erenumab dosage groups versus placebo. Treatment-emergent adverse events were comparable across groups (erenumab, 70 mg: 22.7% and 140 mg: 24.5%; placebo: 25.2%). Conclusion: Both doses of erenumab showed numerical improvement for efficacy endpoints and were well-tolerated in the Indian population. No new safety signals were reported.


How to cite this article:
Chowdhury D, Chaudhuri JR, Ghosh P, Kulkarni R, Singh S, Thakur S, Thorat AV. Efficacy and tolerability of erenumab for prevention of episodic migraine in India.Ann Indian Acad Neurol 2022;25:433-440


How to cite this URL:
Chowdhury D, Chaudhuri JR, Ghosh P, Kulkarni R, Singh S, Thakur S, Thorat AV. Efficacy and tolerability of erenumab for prevention of episodic migraine in India. Ann Indian Acad Neurol [serial online] 2022 [cited 2022 Sep 26 ];25:433-440
Available from: https://www.annalsofian.org/article.asp?issn=0972-2327;year=2022;volume=25;issue=3;spage=433;epage=440;aulast=Chowdhury;type=0